LIFE-CHANGING TECHNOLOGIES, FUELING TOP-TIER, SUSTAINED GROWTH

FIRST-QUARTER 2021 SALES WORLDWIDE

$10.5B in sales

+33.9% on an organic basis*

SALES PERFORMANCE ACROSS ABBOTT

+114.8% DIAGNOSTICS

+8.8% MEDICAL DEVICES

+6.4% NUTRITION

+6.2% ENTREPRENEURIAL ORGANIZATIONS

FULL-YEAR 2021 GUIDANCE REMAINS UNCHANGED

ADJUSTED DILUTED EPS

AT LEAST $5.00

REFLECTING GROWTH OF MORE THAN 35% COMPARABLE TO PRIOR YEAR

GROWTH AND MOMENTUM ACROSS OUR PRODUCT PIPELINE

CARDOVASCULAR

PIPEDLINE ADVANCES IN KEY SEGMENTS

- Strong growth in Structural Heart, Rhythm Management and Electrophysiology
- Expanded reimbursement for MitraClip®
- CE Mark for next-gen TriClip™ device

DIABETES CARE

STRONG GROWTH, GLOBAL LEADERSHIP

- Diabetes Care grew 24% this quarter
- FreeStyle® Libre system now has 3+ million users worldwide

DIAGNOSTICS

NEW BREAKTHROUGHS IN COVID-19 TESTING

- FDA EUA for over-the-counter BinaxNOW™ COVID-19 Self Test® shipping to retailers across the U.S. this week
- Provided nearly 700 million COVID-19 tests since the start of the pandemic

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 20, 2021.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.